Method for treating autoimmune and inflammatory diseases

Abstract

A method for treating autoimmune and inflammatory diseases in a human includes administering an effective amount of a low immunogenic human anti-TNF-α antibody to the human, thereby targeting TNF-α. The low immunogenic human anti-TNF-α antibody includes CDR regions of heavy and light chains from human Adalimumab, and also includes an additional human light chain amino acid sequence, and an additional human heavy chain amino acid sequence. The antibody has reduced immunogenicity compared to Adalimumab.

What is claimed is: 
     
         1 . A method for treating a disease selected from the group consisting of autoimmune and inflammatory diseases in a human, the method comprising administering an effective amount of a low immunogenic human anti-TNF-α antibody to the human, thereby targeting TNF-α,
 wherein the low immunogenic human anti-TNF-α antibody comprises CDR regions of heavy (SEQ ID NO.23) and light (SEQ ID NO.24) chains from human Adalimumab, and further comprises (a) a human light chain amino acid sequence selected from SEQ ID NOs. 11-15 and 23, and (b) a human heavy chain amino acid sequence selected from SEQ ID NOs. 16-20; and 
 wherein the antibody has reduced immunogenicity compared to Adalimumab. 
 
     
     
         2 . The method of  claim 1 , wherein the human light chain amino acid sequence is SEQ ID NO. 13, and wherein the human heavy chain amino acid sequence is SEQ ID NO. 19. 
     
     
         3 . The method of  claim 1 , further comprising:
 administering to the human an additional agent selected from the group consisting of a chemotherapeutic agent, an anti-cell proliferation agent, an immunotherapeutic agent and a combination thereof.   
     
     
         4 . The method of  claim 3 , wherein the at least one therapeutic agent and the additional agent are co-administered to the human. 
     
     
         5 . The method of  claim 3 , wherein the at least one therapeutic agent and the additional agent are co-formulated and are co-administered to the human. 
     
     
         6 . The method of  claim 1 , wherein the administration route is selected from the group consisting of inhalation, oral, rectal, vaginal, parenteral, topical, transdermal, pulmonary, intranasal, buccal, ophthalmic, intrathecal, and a combination thereof. 
     
     
         7 . The method of  claim 1 , wherein the disease is selected from the group consisting of rheumatoid arthritis, Crohn's disease, psoriatic arthritis, and inflammatory bowel disease. 
     
     
         8 . The method of  claim 1 , wherein the disease is rheumatoid arthritis. 
     
     
         9 . The method of  claim 1 , wherein the disease is inflammatory bowel disease. 
     
     
         10 . The method of  claim 1 , wherein the disease is psoriatic arthritis. 
     
     
         11 . The method of  claim 1 , wherein the low immunogenic human anti-TNF-α antibody comprises at least one of the amino acid sequences of L3h4 (SEQ ID NOs. 13 and 19).